326 related articles for article (PubMed ID: 34385178)
1. iPSC-Derived Neoantigen-Specific CTL Therapy for Ewing Sarcoma.
Ishii M; Ando J; Yamazaki S; Toyota T; Ohara K; Furukawa Y; Suehara Y; Nakanishi M; Nakashima K; Ohshima K; Nakauchi H; Ando M
Cancer Immunol Res; 2021 Oct; 9(10):1175-1186. PubMed ID: 34385178
[TBL] [Abstract][Full Text] [Related]
2. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
3. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
Grohar PJ; Segars LE; Yeung C; Pommier Y; D'Incalci M; Mendoza A; Helman LJ
Clin Cancer Res; 2014 Mar; 20(5):1190-203. PubMed ID: 24277455
[TBL] [Abstract][Full Text] [Related]
4. SPOP and OTUD7A Control EWS-FLI1 Protein Stability to Govern Ewing Sarcoma Growth.
Su S; Chen J; Jiang Y; Wang Y; Vital T; Zhang J; Laggner C; Nguyen KT; Zhu Z; Prevatte AW; Barker NK; Herring LE; Davis IJ; Liu P
Adv Sci (Weinh); 2021 Jul; 8(14):e2004846. PubMed ID: 34060252
[TBL] [Abstract][Full Text] [Related]
5. EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma.
Shimizu R; Tanaka M; Tsutsumi S; Aburatani H; Yamazaki Y; Homme M; Kitagawa Y; Nakamura T
Cancer Sci; 2018 Sep; 109(9):2907-2918. PubMed ID: 29945296
[TBL] [Abstract][Full Text] [Related]
6. Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma.
Heisey DAR; Jacob S; Lochmann TL; Kurupi R; Ghotra MS; Calbert ML; Shende M; Maves YK; Koblinski JE; Dozmorov MG; Boikos SA; Benes CH; Faber AC
Mol Cancer Ther; 2021 Oct; 20(10):1868-1879. PubMed ID: 34315769
[TBL] [Abstract][Full Text] [Related]
7. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.
He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K
Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381
[TBL] [Abstract][Full Text] [Related]
8. Ablation of EWS-FLI1 by USP9X inhibition suppresses cancer cell growth in Ewing sarcoma.
Wang S; Huo X; Yang Y; Mo Y; Kollipara RK; Kittler R
Cancer Lett; 2023 Jan; 552():215984. PubMed ID: 36330954
[TBL] [Abstract][Full Text] [Related]
9. EWS-FLI1 perturbs MRTFB/YAP-1/TEAD target gene regulation inhibiting cytoskeletal autoregulatory feedback in Ewing sarcoma.
Katschnig AM; Kauer MO; Schwentner R; Tomazou EM; Mutz CN; Linder M; Sibilia M; Alonso J; Aryee DNT; Kovar H
Oncogene; 2017 Oct; 36(43):5995-6005. PubMed ID: 28671673
[TBL] [Abstract][Full Text] [Related]
10. Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma.
Niedan S; Kauer M; Aryee DN; Kofler R; Schwentner R; Meier A; Pötschger U; Kontny U; Kovar H
Oncogene; 2014 Jul; 33(30):3927-38. PubMed ID: 23995784
[TBL] [Abstract][Full Text] [Related]
11. MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor.
Franzetti GA; Laud-Duval K; Bellanger D; Stern MH; Sastre-Garau X; Delattre O
Oncogene; 2013 Aug; 32(33):3915-21. PubMed ID: 22986530
[TBL] [Abstract][Full Text] [Related]
12. Mithramycin A Radiosensitizes EWS:Fli1
Lin MY; Damron TA; Oest ME; Horton JA
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1454-1471. PubMed ID: 33373655
[TBL] [Abstract][Full Text] [Related]
13. Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis.
Marques Howarth M; Simpson D; Ngok SP; Nieves B; Chen R; Siprashvili Z; Vaka D; Breese MR; Crompton BD; Alexe G; Hawkins DS; Jacobson D; Brunner AL; West R; Mora J; Stegmaier K; Khavari P; Sweet-Cordero EA
J Clin Invest; 2014 Dec; 124(12):5275-90. PubMed ID: 25401475
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.
Rao DD; Jay C; Wang Z; Luo X; Kumar P; Eysenbach H; Ghisoli M; Senzer N; Nemunaitis J
Mol Ther; 2016 Aug; 24(8):1412-22. PubMed ID: 27166877
[TBL] [Abstract][Full Text] [Related]
15. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.
Grohar PJ; Woldemichael GM; Griffin LB; Mendoza A; Chen QR; Yeung C; Currier DG; Davis S; Khanna C; Khan J; McMahon JB; Helman LJ
J Natl Cancer Inst; 2011 Jun; 103(12):962-78. PubMed ID: 21653923
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of HDACs reduces Ewing sarcoma tumor growth through EWS-FLI1 protein destabilization.
Pedot G; Marques JG; Ambühl PP; Wachtel M; Kasper S; Ngo QA; Niggli FK; Schäfer BW
Neoplasia; 2022 May; 27():100784. PubMed ID: 35366465
[TBL] [Abstract][Full Text] [Related]
17. Junction region of EWS-FLI1 fusion protein has a dominant negative effect in Ewing's sarcoma in vitro.
Jully B; Vijayalakshmi R; Gopal G; Sabitha K; Rajkumar T
BMC Cancer; 2012 Nov; 12():513. PubMed ID: 23145994
[TBL] [Abstract][Full Text] [Related]
18. EWS::FLI1 and HOXD13 Control Tumor Cell Plasticity in Ewing Sarcoma.
Apfelbaum AA; Wu F; Hawkins AG; Magnuson B; Jiménez JA; Taylor SD; Wrenn ED; Waltner O; Pfaltzgraff ER; Song JY; Hall C; Wellik DM; Ljungman M; Furlan SN; Ryan RJH; Sarthy JF; Lawlor ER
Clin Cancer Res; 2022 Oct; 28(20):4466-4478. PubMed ID: 35653119
[TBL] [Abstract][Full Text] [Related]
19. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
[TBL] [Abstract][Full Text] [Related]
20. EWS-FLI1 and Menin Converge to Regulate ATF4 Activity in Ewing Sarcoma.
Jiménez JA; Apfelbaum AA; Hawkins AG; Svoboda LK; Kumar A; Ruiz RO; Garcia AX; Haarer E; Nwosu ZC; Bradin J; Purohit T; Chen D; Cierpicki T; Grembecka J; Lyssiotis CA; Lawlor ER
Mol Cancer Res; 2021 Jul; 19(7):1182-1195. PubMed ID: 33741715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]